Real-world evidence (RWE) supports the efficacy of Ibrance plus letrozole in breast cancer

• Data published in Breast Cancer Research showed real-world efficacy of palbociclib (Ibrance) in combination with letrozole in women with hormone receptor–positive, HER2-negative metastatic breast cancer versus letrozole alone
• These findings which showed extended overall and progression-free survival (PFS) benefit with the combination represents the first comprehensive comparative effectiveness analysis of outcomes for a CDK4/6 inhibitor in clinical practice
• “Real-world evidence is woven into the fabric of how we innovate and advance care for patients with breast cancer, supporting our randomized clinical trials
• With more than 6 years of patient experience, a positive benefit-risk profile, strong clinical data, and robust real-world data, the totality of evidence solidifies the role of palbociclib plus endocrine therapy as a treatment for patients with metastatic breast cancer.”

Chris Boshoff, MD, PhD, Chief Development Officer, Oncology, Pfizer Global Product Development

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.

About DISTILL

DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Ref: RWEAPR2022GSA